Case report
Mrs. Beauty Begum, 35 years old housewife, mother of two kids, hailing from Tangail presented with the complaints of intermittent fever, generalized bodyache, multiple joints pain with swelling involving hands, knees and ankles for the 3 months duration. She did not have any morning stiffness, skin nodules or shortness of breathing. She also noticed that her skin of face, forehead, arms and fore-arms has become tightened for 1 month. On further query, she added that she is having pain and numbness of hands while handling water (especially cold). There is change in skin colour and experienced pain under the skin which is not related to the joint pain. She does not give any history of leg swelling, chest pain, dryness of eyes or mouth, difficulty in swallowing or hair loss.
On clinical examination, she had expressionless face, tight and glistening skin of face with loss of wrinkles on forehead. The perioral skin area was tightened and she could not open her mouth fully as she could have previously. The skin of arm, fore-arm was tightened and fingers examination revealed sclerodactyly with superficial ulcers in metacarpophalangeal and interphalangeal joints of both hands. There is pain, swelling and tenderness of joints of hands, ankles and knees but no deformity. There was no cervical spine or joints lower back involved. MCTD is now recognized to occur throughout the world. It is predominantly a disease of females, with female to male ratio of 16:1 4 . The disease is seen among all age groups range from 4 -80 years; the mean age of onset in adult is 35 years. There is both T-cell & B cell response with less immune complex formation.
The characteristic lesions in the involved organs are intensive obliterative, proliferative vascular lesions in large, medium and small vessels with less inflammatory infiltrates.
In the early phases of the MCTD many patients complain of easy fatigability poorly defined myalgias, arthralgias and Raynaud's phenomenon; systemic involvements are as followsl Fever of unknown origin may be the presenting feature of MCTD 5 . The most common skin change is the Raynaud's phenomenon, others are malar rash, generalized erythematous rash.
l Raynaud's phenomenon is seen in 75%-100% of patients. Approximately 60 percent of patients develop an obvious arthritis. Myalgias and myositis can be seen in 30%-50% of patients.
l The gastrointestinal symptoms may range from heartburn, dysphagia, diarrhea and symptoms of malabsorption. Disordered motility in the upper gastrointestinal tract is the commonest problem 6 .
l Pleuropulmonary involvement is common, it may be asymptomatic or the patient may present with pleurisy and effusion, interstitial lung disease, pulmonary arterial hypertension (PAH) 7 .
l All three layers of the heart may be involved in MCTD with abnormal ECG findings 8 .
l Neurological manifestations are less common, presenting as aseptic meningitis, trigeminal neuralgia, demyelination, transverse myelitis and peripheral neuropathy. The laboratory findings are anemia, leucopenia, elevated erythrocyte sedimentation rate, hypergammaglobulinemia (100%), positive combs test, and Rheumatoid factor positive in 50 to 70% of patients 9 . Antinuclear antibody positivity is seen in 100% of patients in high titre with coarse speckled pattern. Anti U1RNP antibodies by haemagglutination test is highly characteristic feature of MCTD. Many patients also make antibodies directed against hnRNP-A2, fibrillin-1, and nucleosomes, but not to RNA polymerases 10 . The absence of anti-Sm antibodies and anti-DNA antibodies in a seropositive for anti U1RNP is an important discriminating finding for MCTD from SLE 13 . Also scleroderma-specific antibodies, including anticentromere and anti-Scl-70 (topoisomerase) are absent 13 . Antiphospholipid antibodies occur, but are less common than in those with SLE 11 .
No controlled trials have been performed to guide therapy. Instead, the management of patients with MCTD generally rests upon the effectiveness of specific therapies for similar problems seen in SLE, scleroderma, or polymyositis. By comparison, scleroderma-like features (eg, Raynaud phenomenon, pulmonary hypertension) are usually less responsive to therapy. NSAIDs are given for pain, calcium channel blockers for PAH, Immunosuppression (steroid and other agents) is particularly required in cases with severe arthritis, pulmonary hypertension and serositis involving pericardium or pleura.
MCTD has relatively good prognosis in view of low prevalence of serious renal disease and life-threatening neurologic problems. Morbidity is quite high in patients with MCTD due to multiple factors including recurrent musculoskeletal pain, fibromyalgia, gastroesophageal acid reflux etc. Mortality associated with MCTD ranges, in different studies, from 16 to 28 percent at 10 to 12 years 12 . Those patients with more features of scleroderma and polymyositis had a worse prognosis. The major causes of death include progressive pulmonary hypertension and its cardiac complications.
